S&P 및 Nasdaq 내재가치 문의하기

Cumberland Pharmaceuticals Inc. CPIX NASDAQ

NASDAQ Global Select • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
38/100
1/6 Pass
SharesGrow Intrinsic Value
$5.57
+75.2%

Cumberland Pharmaceuticals Inc. (CPIX) 은(는) 상장 기업입니다 헬스케어 섹터의 Drug Manufacturers - Specialty & Generic 산업에서 운영. 본사 소재지는 Nashville, TN, 미국. 현재 CEO는 A. J. Kazimi.

CPIX 을(를) 보유 IPO 날짜 2009-08-11, 91 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $47.56M.

Cumberland Pharmaceuticals Inc. 소개

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

📍 2525 West End Avenue, Nashville, TN 37203 📞 615 255 0068
회사 세부정보
섹터헬스케어
산업Drug Manufacturers - Specialty & Generic
국가미국
거래소NASDAQ Global Select
통화USD
IPO 날짜2009-08-11
CEOA. J. Kazimi
직원 수91
거래 정보
현재 가격$3.18
시가역액$47.56M
52주 범위1.85-6.27
베타-0.33
ETF아니오
ADR아니오
CUSIP230770109
문의하기
🎓
SharesGrow 아카데미
내재가치 계산법과 저평가 종목 찾기를 배우세요.
주간 라이브 세션
메시지 보내기